Plasma Circulating Terminal Differentiation–Induced Non-Coding RNA Serves as a Biomarker in Breast Cancer
,
Abstract
Background: Breast cancer is identified as the most common malignancy and cause of cancer-related death worldwide. Compared with healthy controls, this study evaluated the expression level and diagnostic power of lncRNA plasma TINCR in breast cancer patients.
Materials and Methods: Fifty-eight women diagnosed with invasive ductal carcinoma and fifty healthy age-matched controls were included in the study. TRIzol® LS regent was used to isolate the total RNA from the whole plasma. Total RNA was converted to cDNA using Prime ScriptTM RT reagent kit and the expression levels of TINCR were quantified by qRT-PCR.
Results: Low levels of TINCR lncRNA were observed in the plasma of breast cancer patients compared with control subjects. Plasma TINCR level was also positively correlated with the diagnostic age of breast cancer patients.
Conclusion: A low level of plasma TINCR could discriminate breast cancer patients from healthy control subjects.
1. Jazayeri SB, Saadat S, Ramezani R, et al. Incidence of primary breast cancer in Iran: Ten-year national cancer registry data report. Cancer Epidemiol. 2015; 39 (4):519-27.
2. Agarwal G, Pradeep PV, Aggarwal V, et al. Spectrum of breast cancer in Asian women. World J Surg. 2007; 31(5):1031-40.
3. Fazel A, Hasanpour-Heidari S, Salamat F, et al. Marked increase in breast cancer incidence in young women: A 10-year study from Northern Iran, 2004-2013. Cancer Epidemiol. 2019; 62:101573.
4. Taheri NS, Bakhshandehnosrat S, Tabiei MN, et al. Epidemiological pattern of breast cancer in Iranian women: is there an ethnic disparity? Asian Pac J Cancer Prev. 2012; 13 (9):4517-20.
5. Kim Y, Yoo KY, Goodman MT. Differences in incidence, mortality and survival of breast cancer by regions and countries in Asia and contributing factors. Asian Pac J Cancer Prev. 2015;16 (7):2857-70.
6. Thakur P, Seam RK, Gupta MK, et al. Breast cancer risk factor evaluation in a Western Himalayan state: A case–control study and comparison with the Western World. South Asian J Cancer. 2017; 6 (3):106-9.
7. Rinn JL, Chang HY. Long Noncoding RNAs. Molecular Modalities to Organismal Functions. Annu Rev Biochem. 2020; 89:283-308.
8. Ghasemi T, Khalaj-Kondori M, Hosseinpour Feizi MA, et al. lncRNA-miRNA-mRNA interaction network for colorectal cancer; An in silico analysis. Comput Biol Chem. 2020; 89:107370.
9. Kretz M, Siprashvili Z, Chu C, et al. Control of somatic tissue differentiation by the long non-coding RNA TINCR. Nature. 2013; 493(7431):231-5.
10. Iwakiri J, Terai G, Hamada M. Computational prediction of lncRNA-mRNA interactionsby integrating tissue specificity in human transcriptome. Biol Direct. 2017; 12 (1):15.
11. Xu TP, Liu XX, Xia R, et al. SP1-induced upregulation of the long noncoding RNA TINCR regulates cell proliferation and apoptosis by affecting KLF2 mRNA stability in gastric cancer. Oncogene. 2015; 34(45):5648-61.
12. Xia H, Xiu M, Gao J, et al. LncRNA PLAC 2 downregulated miR-21 in non-small cell lung cancer and predicted survival. BMC Pulm Med. 2019; 19(1):172.
13. Tao S, Wang L, Zhu Z, et al. Adverse effects of bisphenol A on Sertoli cell blood-testis barrier in rare minnow Gobiocypris rarus. Ecotoxicol Environ Saf. 2019;171:475-83.
14. Chen F, Qi S, Zhang X, et al. lncRNA PLAC2 activated by H3K27 acetylation promotes cell proliferation and invasion via the activation of Wnt/betacatenin pathway in oral squamous cell carcinoma. Int J Oncol. 2019; 54 (4):1183-94.
15. Rizzacasa B, Morini E, Mango R, et al. Comparative Ct method quantification (2-ΔCt method). protocols.io. 2019. ttps://dx.doi.org/10.17504/protocols.io.zp7f5rn.
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4):402-8.
17. Shibuya K, Mathers CD, Boschi-Pinto C, et al. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer. 2002; 2:37.
18. Komoike Y, Akiyama F, Iino Y, et al. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Cancer. 2006; 106(1):35-41.
19. Ono Y, Yoshimura M, Hirata K, et al. The impact of age on the risk of ipsilateral breast tumor recurrence after breast-conserving therapy in breast cancer patients with a > 5 mm margin treated without boost irradiation. Radiat Oncol. 2019; 14(1):121.
20. Han W, Kang SY, Korean Breast Cancer Society. Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res Treat. 2010;119(1):193-200.
21. Barber MD, Jack W, Dixon JM. Diagnostic delay in breast cancer. Br J Surg. 2004:91. (1):49-53.
22. Wong FY, Tham WY, Nei WL, et al. Age exerts a continuous effect in the outcomes of Asian breast cancer patients treated with breast-conserving therapy. Cancer Commun (Lond). 2018; 38 (1):39.
23. Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology. 2002; 225(1):165-75.
24. Shah TA, Guraya SS. Breast cancer screening programs: Review of merits, demerits, and recent recommendations practiced across the world. J Microsc Ultrastruct. 2017; 5(2):59-69.
25. Yu S, Wang D, Shao Y, et al. SP1-induced lncRNA TINCR overexpression contributes to colorectal cancer progression by sponging miR-7-5p. Aging (Albany NY). 2019; 11(5):1389-1403.
26. Zhang K, Shi H, Xi H, et al. Genome-Wide lncRNA Microarray Profiling Identifies Novel Circulating lncRNAs for Detection of Gastric Cancer. Theranostics. 2017;7(1):213-227.
27. Zhuang Z, Huang J, Wang W, et al. Down-Regulation of Long Non-Coding RNA TINCR Induces Cell Dedifferentiation and Predicts Progression in Oral Squamous Cell Carcinoma. Front Oncol. 2021;10:624752.
28. Liu X, Ma J, Xu F, et al. TINCR suppresses proliferation and invasion through regulating miR-544a/FBXW7 axis in lung cancer. Biomed Pharmacother. 2018; 99:9-17.
29. Dong L, Ding H, Li Y, et al. LncRNA TINCR is associated with clinical progression and serves as tumor suppressive role in prostate cancer. Cancer Manag Res. 2018;10:2799-807.
30. Wang X, Li S, Xiao H, et al. Serum lncRNA TINCR Serve as a Novel Biomarker for Predicting the Prognosis in Triple-Negative Breast Cancer. Technol Cancer Res Treat. 2020; 19:1533033820965574.
31. Xu S, Kong D, Chen Q, et al. Oncogenic long noncoding RNA landscape in breast cancer. Mol Cancer. 2017; 16(1):129.
2. Agarwal G, Pradeep PV, Aggarwal V, et al. Spectrum of breast cancer in Asian women. World J Surg. 2007; 31(5):1031-40.
3. Fazel A, Hasanpour-Heidari S, Salamat F, et al. Marked increase in breast cancer incidence in young women: A 10-year study from Northern Iran, 2004-2013. Cancer Epidemiol. 2019; 62:101573.
4. Taheri NS, Bakhshandehnosrat S, Tabiei MN, et al. Epidemiological pattern of breast cancer in Iranian women: is there an ethnic disparity? Asian Pac J Cancer Prev. 2012; 13 (9):4517-20.
5. Kim Y, Yoo KY, Goodman MT. Differences in incidence, mortality and survival of breast cancer by regions and countries in Asia and contributing factors. Asian Pac J Cancer Prev. 2015;16 (7):2857-70.
6. Thakur P, Seam RK, Gupta MK, et al. Breast cancer risk factor evaluation in a Western Himalayan state: A case–control study and comparison with the Western World. South Asian J Cancer. 2017; 6 (3):106-9.
7. Rinn JL, Chang HY. Long Noncoding RNAs. Molecular Modalities to Organismal Functions. Annu Rev Biochem. 2020; 89:283-308.
8. Ghasemi T, Khalaj-Kondori M, Hosseinpour Feizi MA, et al. lncRNA-miRNA-mRNA interaction network for colorectal cancer; An in silico analysis. Comput Biol Chem. 2020; 89:107370.
9. Kretz M, Siprashvili Z, Chu C, et al. Control of somatic tissue differentiation by the long non-coding RNA TINCR. Nature. 2013; 493(7431):231-5.
10. Iwakiri J, Terai G, Hamada M. Computational prediction of lncRNA-mRNA interactionsby integrating tissue specificity in human transcriptome. Biol Direct. 2017; 12 (1):15.
11. Xu TP, Liu XX, Xia R, et al. SP1-induced upregulation of the long noncoding RNA TINCR regulates cell proliferation and apoptosis by affecting KLF2 mRNA stability in gastric cancer. Oncogene. 2015; 34(45):5648-61.
12. Xia H, Xiu M, Gao J, et al. LncRNA PLAC 2 downregulated miR-21 in non-small cell lung cancer and predicted survival. BMC Pulm Med. 2019; 19(1):172.
13. Tao S, Wang L, Zhu Z, et al. Adverse effects of bisphenol A on Sertoli cell blood-testis barrier in rare minnow Gobiocypris rarus. Ecotoxicol Environ Saf. 2019;171:475-83.
14. Chen F, Qi S, Zhang X, et al. lncRNA PLAC2 activated by H3K27 acetylation promotes cell proliferation and invasion via the activation of Wnt/betacatenin pathway in oral squamous cell carcinoma. Int J Oncol. 2019; 54 (4):1183-94.
15. Rizzacasa B, Morini E, Mango R, et al. Comparative Ct method quantification (2-ΔCt method). protocols.io. 2019. ttps://dx.doi.org/10.17504/protocols.io.zp7f5rn.
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4):402-8.
17. Shibuya K, Mathers CD, Boschi-Pinto C, et al. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer. 2002; 2:37.
18. Komoike Y, Akiyama F, Iino Y, et al. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Cancer. 2006; 106(1):35-41.
19. Ono Y, Yoshimura M, Hirata K, et al. The impact of age on the risk of ipsilateral breast tumor recurrence after breast-conserving therapy in breast cancer patients with a > 5 mm margin treated without boost irradiation. Radiat Oncol. 2019; 14(1):121.
20. Han W, Kang SY, Korean Breast Cancer Society. Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res Treat. 2010;119(1):193-200.
21. Barber MD, Jack W, Dixon JM. Diagnostic delay in breast cancer. Br J Surg. 2004:91. (1):49-53.
22. Wong FY, Tham WY, Nei WL, et al. Age exerts a continuous effect in the outcomes of Asian breast cancer patients treated with breast-conserving therapy. Cancer Commun (Lond). 2018; 38 (1):39.
23. Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology. 2002; 225(1):165-75.
24. Shah TA, Guraya SS. Breast cancer screening programs: Review of merits, demerits, and recent recommendations practiced across the world. J Microsc Ultrastruct. 2017; 5(2):59-69.
25. Yu S, Wang D, Shao Y, et al. SP1-induced lncRNA TINCR overexpression contributes to colorectal cancer progression by sponging miR-7-5p. Aging (Albany NY). 2019; 11(5):1389-1403.
26. Zhang K, Shi H, Xi H, et al. Genome-Wide lncRNA Microarray Profiling Identifies Novel Circulating lncRNAs for Detection of Gastric Cancer. Theranostics. 2017;7(1):213-227.
27. Zhuang Z, Huang J, Wang W, et al. Down-Regulation of Long Non-Coding RNA TINCR Induces Cell Dedifferentiation and Predicts Progression in Oral Squamous Cell Carcinoma. Front Oncol. 2021;10:624752.
28. Liu X, Ma J, Xu F, et al. TINCR suppresses proliferation and invasion through regulating miR-544a/FBXW7 axis in lung cancer. Biomed Pharmacother. 2018; 99:9-17.
29. Dong L, Ding H, Li Y, et al. LncRNA TINCR is associated with clinical progression and serves as tumor suppressive role in prostate cancer. Cancer Manag Res. 2018;10:2799-807.
30. Wang X, Li S, Xiao H, et al. Serum lncRNA TINCR Serve as a Novel Biomarker for Predicting the Prognosis in Triple-Negative Breast Cancer. Technol Cancer Res Treat. 2020; 19:1533033820965574.
31. Xu S, Kong D, Chen Q, et al. Oncogenic long noncoding RNA landscape in breast cancer. Mol Cancer. 2017; 16(1):129.
| Files | ||
| Issue | Vol 18, No 1 (2024) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijhoscr.v18i1.14739 | |
| Keywords | ||
| Breast cancer; TINCR; Plasma | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Shaghaghi Torkdari Z, Khalaj-Kondori M, Hosseinpour Feizi MA. Plasma Circulating Terminal Differentiation–Induced Non-Coding RNA Serves as a Biomarker in Breast Cancer. Int J Hematol Oncol Stem Cell Res. 2024;18(1):1-6.
